The QualityStocks Daily Thursday, July 7th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(DRMA) $0.6902 +32.73%

Schaeffer's(BBBY) $5.4400 +21.70%

MarketClub Analysis(FFIE) $5.5000 +21.15%

The QualityStocks Daily Stock List

Target Hospitality Corp. (TH)

MarketBeat, QualityStocks, Zacks, Super Stock Picker, TradersPro, InvestorPlace, StreetInsider, MarketClub Analysis, StockMarketWatch, Trades Of The Day, Streetwise Reports, StocksEarning, and Daily Trade Alert reported earlier on Target Hospitality Corp. (TH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Target Hospitality Corp. is the largest provider of vertically-integrated specialty hospitality accommodations with first-rate catering and value-added hospitality services in the United States. The Company builds, owns, and also operates customized housing communities for a range of end users. Target Hospitality provides a complete set of cost-effective hospitality solutions. These include culinary, catering, concierge, laundry, security services, and recreational facilities. Target Hospitality is based in The Woodlands, Texas. The Company lists on the Nasdaq Global Select Market.

Target Hospitality is a worldwide provider of turnkey accommodations and hospitality solutions. It coordinates every component of building and operating a workforce lodging community. The Company custom builds workforce housing accommodations to fulfill any need or specification. This is from basketball courts to BBQ pits, catering to housekeeping services, 24-hour travel professionals to on-site transportation management.

The Company chiefly serves the energy and government sectors. It handles everything and outsources nothing. The design of its increasing network of 25 communities with greater than 13,000 rooms is to maximize workforce productivity and satisfaction.

Target Hospitality has its Lodge Network. Its existing lodges provide value to companies and accommodations. Target provides a totally operating Housing Community that is already up and running. It offers turnkey accommodations and hospitality solutions.

The Company’s oil field hospitality and lodge management services include Catering; Accounting; Security, and Communications. Furthwermore, Oil field hospitality and lodge management services include Maintenance/Housekeeping; Laundry; HSE, as well as Quality Control/Assurance.

Regarding Temporary Workforce Housing, Target Hospitality provides temporary oil field housing, temporary apartments in an Olympic village, or housing for disaster relief workers. It customizes to a client’s requirements and preferences. Moreover, it provides short-term, long-term, affordable, and comfortable turnkey accommodations and hospitality solutions.

Target Hospitality has been awarded the GSA Professional Services Schedule (PSS) contract enabling it to provide logistics solutions to government agencies. The Company provides a wide array of housing, deployment, operations, and management services through its GSA Professional Services Schedule agreement.

Target Hospitality Corp. (TH), closed Thursday's trading session at $6.05, up 22.2222%, on 770,331 volume. The average volume for the last 3 months is 770,331 and the stock's 52-week low/high is $2.72/$7.68.

Bolt Biotherapeutics (BOLT)

Wall Street Resources, SmarTrend Newsletters, MarketBeat, Zacks, QualityStocks, WealthMakers, InvestorPlace, GorillaTrades, Barchart and AllPennyStocks reported earlier on Bolt Biotherapeutics (BOLT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bolt Biotherapeutics Inc. (NASDAQ: BOLT) (FRA: 6LP) is a clinical-stage immune-oncology firm that is focused on discovering, developing and commercializing pharmaceutical products.

The firm has its headquarters in Redwood City, California and was incorporated in 2015. Prior to its name change in July 2015, the firm was known as Bolt Therapeutics Inc. It serves consumers in the United States.

The company is committed to delivering transformative treatments to cancer patients whose medical needs haven’t been met. It is pioneering new targeted immunotherapies which leverage the activation of the adaptive and innate immune systems in the microenvironment of a tumor with the precision of antibody targeting. The company’s immune-stimulating antibody conjugates uncover the immune system to induce anti-tumor immunity.

The enterprise’s product pipeline comprises of a carcinoembryonic antigen program, dubbed BDC-2034, indicated for the treatment of breast cancer, pancreatic cancer, non-small cell lung cancer and colorectal cancer. It also develops a HER2 (human epidermal growth factor receptor 2) known as BDC-1001, to treat patients with HER2-expressing solid tumors, which includes HER2-low tumors. In addition to this, the enterprise develops a programmed cell death-ligand 1 program for tumors that aren’t responsive to immune checkpoint blockade; and a myeloid modulator platform which reawakens myeloid cells to attack tumor cells.

The firm recently announced interim clinical data from its BDC-1001 phase I/II study, which shows early indications of clinical disease control as well as a favorable safety profile. The success and approval of the formulation will not only benefit patients but also bring in more investors into the firm, which will be good for its growth.

Bolt Biotherapeutics (BOLT), closed Thursday's trading session at $2.49, up 22.0588%, on 898,152 volume. The average volume for the last 3 months is 898,152 and the stock's 52-week low/high is $1.39/$19.285.

Dermata Therapeutics (DRMA)

QualityStocks and MarketBeat reported earlier on Dermata Therapeutics (DRMA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Dermata Therapeutics Inc. (NASDAQ: DRMA) is a clinical-stage biotechnology firm that is focused on treating aesthetic and medical skin conditions.

The firm has its headquarters in San Diego, California and was incorporated in December 2014 by Gerald T. Proehl and David F. Hale. The firm serves consumers around the globe.

The company believes it has the potential to address various facets of psoriasis vulgaris, acne rosacea, acne vulgaris and other multiple aesthetic areas with high unmet clinical needs. Its business strategy is to identify and develop innovative products that can be moved into clinical trials to demonstrate their safety and effectiveness in treating various indications.

The enterprise’s product portfolio is comprised of product candidates it has developed using its Spongilla platform technology. The technology is based on the use of Songillalacustris, a freshwater sponge which naturally grows in lakes and rivers in commercial quantities in different parts of the globe. The enterprise’s candidates include a once-a-week topical formulation dubbed DMT310, which is under clinical development and is indicated for the treatment of papulopustular rosacea, psoriasis vulgaris and acne vulgaris. It also develops a formulation dubbed DMT410, for the treatment of various aesthetic conditions like hyperhidrosis.

The firm recently announced its latest financial results, with its CEO noting that they were focused on advancing the firm’s clinical pipeline for multiple indications having released positive topline results from its DMT310 clinical trial. The success and approval of the firm’s formulations will bring in additional revenue as well as investors, which will be good for its growth.

Dermata Therapeutics (DRMA), closed Thursday's trading session at $0.6902, up 32.7308%, on 17,334,060 volume. The average volume for the last 3 months is 17.334M and the stock's 52-week low/high is $0.435/$6.95.

Magenta Therapeutics (MGTA)

MarketBeat, Trades Of The Day, StreetInsider, QualityStocks, Daily Trade Alert, The Online Investor, StockMarketWatch, Schaeffer's, InvestorPlace and BUYINS.NET reported earlier on Magenta Therapeutics (MGTA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Magenta Therapeutics Inc. (NASDAQ: MGTA) (FRA: 3MT) is a clinical-stage biotechnology firm that is focused on the development of new medicines that utilize the power of genome editing, gene therapy, stem cell transplants and cell therapy.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in 2015, on June 17th by Jason Gardner, John F. Dipersio, Robert Negrin, Luigi Naldini, Alan Tyndall, Derrick Rossi and David Scadden. Prior to its name change in February 2016, the firm was known as HSCTCo Therapeutics Inc. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has two companies in its corporate family and serves consumers in the United States.

The company’s aim is to revolutionize stem cell transplants as the treatment for a range of blood and immune illnesses. Stem cell transplants are a curative approach for various blood cancers. However, this is rarely used in non-cancerous indications because of the toxicities linked to the transplant procedure.

The enterprise’s product pipeline comprises of a candidate dubbed MGTA-145, to control mobilization of stem cells; an aryl hydrocarbon receptor antagonist known as E478, for gene-modified stem cell expansion; an allogeneic stem cell therapy dubbed MGTA-456, for stem cell growth control; C300 and C100 antibody drug conjugates for transplant conditioning; and an antibody-drug conjugate program known as G100, which hinders graft-vs-host ailments prophylaxis.

The firm is focused on advancing its pipeline, in an attempt to improve eligibility for future gene therapies. This will not only benefit patients suffering from a range of indications but also revolutionize the treatment of some of these diseases and bring in additional revenue into the firm.

Magenta Therapeutics (MGTA), closed Thursday's trading session at $1.7, up 29.771%, on 343,611 volume. The average volume for the last 3 months is 343,611 and the stock's 52-week low/high is $0.9231/$9.86.

Full House Resorts (FLL)

Wall Street Resources, InvestorPlace, TradersPro, MarketBeat,, StreetInsider, SmarTrend Newsletters, GorillaTrades, FNNO Newsletters, StockMarketWatch, Wealth Insider Alert, Zacks, MegaPennyStocks, StreetAuthority Daily, FreeRealTime, Penny Invest, First Penny Picks, MarketClub Analysis, OTCBB Journal, QualityStocks, Short Term Wealth, Daily Trade Alert, SmallCapVoice, StockEgg, StockOodles, StocksImpossible, The Bowser Report, The Street, Trader Prep, Trades Of The Day and SmallCapReview reported earlier on Full House Resorts (FLL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Full House Resorts, Inc. (NASDAQ: FLL) (FRA: F4L) is focused on developing, owning, operating, managing and leasing casinos and related entertainment and hospitality facilities.

The firm has its headquarters in Las Vegas, Nevada and was incorporated in 1987, on January 5th. It operates as part of the resorts and casinos industry, under the consumer cyclical sector. The firm serves consumers in the United States.

The company operates through the Northern Nevada, Rising Star Casino Resort, Bronco Billy’s Casino and Hotel and Silver Slipper Casino and Hotel segments. The Northern Nevada segment covers the Grand Lodge Casino and Stockman’s Casino while the Rising Star segment comprises of a multi-purpose grand theater, coffee shops, casino space, quick service restaurants, sports bars, buffets, fine dining restaurants and hotels. On the other hand, the Bronco Billy segment contains video poker and slot machines, an outdoor amphitheater, casual dining outlets, steakhouses, hotel rooms and table games. The Silver Slipper segment includes casino bars, quick service restaurants, buffets, fine dining restaurants, hotel rooms and gaming space. Its casino operations are managed in the U.S.A. The company generates the majority of its revenues from the gaming sources, which include revenues from sports betting, keno, table games and slot machines.

The enterprise remains focused on making progress on its expansion plans, as this will help generate significant revenues while also helping create shareholder value. This is in addition to opening the enterprise up to new opportunities and bringing in more investors into the firm.

Full House Resorts (FLL), closed Thursday's trading session at $5.82, up 6.3985%, on 279,014 volume. The average volume for the last 3 months is 279,014 and the stock's 52-week low/high is $4.82/$12.57.

Momentive Global (MNTV)

Schaeffer's, Trades Of The Day, MarketBeat and Daily Trade Alert reported earlier on Momentive Global (MNTV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Momentive Global Inc. (NASDAQ: MNTV) (FRA: 2K90) is an experience management firm that is engaged in the provision of Software-as-a-Service solutions that enable businesses to turn stakeholder feedback into action.

The firm has its headquarters in San Mateo, California and was incorporated in 1999 by Ryan Finley. Prior to its name change in June 2021, the firm was known as SVMK Inc. It operates as part of the software-application industry, under the technology sector. The firm serves consumers around the globe, with a focus on the United States.

The enterprise provides the GetFeedback CX platform, which allows firms to leverage consumer feedback to retain and engage their customers; survey software products under the SurveyMonkey brand, which allows customers to take action on shareholder feedback; a marketing content automation solution known as TechValidate; and GetFeedback Pro, which includes essential features and adds advanced automation, analytics and additional pre-built integrations as well as feedback collection channels. It also offers GetFeedback Ultimate, which is comprised of features from the GetFeedback Pro, and allows single sign-on; Wufoo, which enables users to create mobile and web forms; an application management solution dubbed SurveyMonkey Apply; and the Audience panel, which allows companies to collect and analyze actionable data from targeted panelists. The enterprise serves government agencies, media and entertainment, healthcare, technology, financial services, energy, manufacturing and not-for-profit organizations.

The company’s recently released financial results show increases in its revenues, with its CEO noting that they were committed to driving profitable growth. This will help generate value for its shareholders and bring in additional revenues.

Momentive Global (MNTV), closed Thursday's trading session at $9.71, up 4.2965%, on 1,115,843 volume. The average volume for the last 3 months is 1.092M and the stock's 52-week low/high is $8.55/$25.00.

Enjoy Technology (ENJY)

MarketBeat reported earlier on Enjoy Technology (ENJY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Enjoy Technology Inc. (NASDAQ: ENJY) is a technology-powered service platform which operates mobile retail stores, providing same-day delivery services.

The firm has its headquarters in Palo Alto, California and was incorporated in May 2014 by Tom Suiter and Ronald B. Johnson. It operates as part of the specialty retail industry, under the consumer cyclical sector. The firm serves consumers in the United States.

The company has established multi-year commercial relationships with leading consumer brands to bring services, products and subscriptions into the homes of consumers conveniently and comfortably. It operates through the Europe and the North America segments. The former segment includes operations within the United Kingdom while the latter segment is comprised of operations in Canada and the United States. The company derives most of its revenues from its North America segment.

The enterprise has pioneered a new retail experience which can do everything a traditional retail experience does, via its mobile stores. Its offerings include the Smart Last Mile, which offers its business partners an omni-channel solution that allows for trusted to-the-door deliveries and at-home retail experiences. The enterprise also delivers a range of technology and telecommunications accessories and products. This is in addition to assisting consumers in selecting and evaluating a myriad of protection, media sources, accessories, broadband and other services.

The firm remains focused on executing its strategic plan to deliver results for its partners. This will help create value for its shareholders while also bolstering its growth and boosting investments into the firm.

Enjoy Technology (ENJY), closed Thursday's trading session at $0.401, off by 4.2959%, on 18,651,345 volume. The average volume for the last 3 months is 16.92M and the stock's 52-week low/high is $0.1228/$12.0204.

Cryo-Cell International (CCEL)

Wall Street Resources, SmarTrend Newsletters, MarketBeat, SmallCapVoice,, QualityStocks, M2 Communications, PennyTrader Publisher, PennyToBuck, PennyOmega, StockHotTips, BestOtc, FeedBlitz, DrStockPick, CRWEWallStreet, CRWEPicks, CRWEFinance and OTC Advisors reported earlier on Cryo-Cell International (CCEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cryo-Cell International, Inc. (NASDAQ: CCEL) (FRA: ZCY) is a cord blood bank, which is focused on cellular processing and cryogenic cellular storage, with a primary focus on collecting and preserving umbilical cord blood stem cells for family use.

The firm has its headquarters in Oldsmar, Florida and was incorporated in 1989. It operates as part of the medical care facilities industry, under the healthcare sector. The firm serves consumers in the United States.

The company operates through the Prepacyte CB, Cellular processing and Cryogenic storage segments. Prepacyte CB is the processing technology utilized in the processing of blood stem cells from the umbilical cord. On the other hand, the Cellular processing and cryogenic storage segment is involved in collecting and preserving of umbilical cord tissue and blood stem cells for family use.

The enterprise’s cord tissue service stores sections of umbilical cord tissues, which are sources of mesenchymal stem cells that can be used in regenerative medicine to treat various conditions, including auto-immune illnesses, wound healing, ALS, kidney disease and heart disease. It stores roughly 500,000 cord tissue and cord blood stem cells globally. The enterprise markets its preservation services directly to expectant partners, as well as distributes information through certified nurse-midwives, childbirth educators, pediatricians, obstetricians and other related healthcare professionals.

The firm recently announced its latest financial results, which show an increase in its revenues and income. It remains focused on investing in various projects that will allow them to treat patients who need innovative care with cellular therapies. This will not only benefit these patients but also encourage more investments into the firm.

Cryo-Cell International (CCEL), closed Thursday's trading session at $5.76, even for the day, on 701 volume. The average volume for the last 3 months is 701 and the stock's 52-week low/high is $5.75/$14.16.

Rent the Runway Inc. (RENT)

RedChip, StreetInsider, SmarTrend Newsletters, StreetAuthority Daily,, The Street, Stockhouse, CNBC Breaking News, Dynamic Wealth Report, FeedBlitz, FNNO Newsletters, Greenbackers, InvestorPlace,, MarketBeat, AllPennyStocks, National Inflation Association, TradingMarkets, Schaeffer's, SpeculatingStocks, TopStockAnalysts and Money Morning reported earlier on Rent the Runway Inc. (RENT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Rent the Runway Inc. (NASDAQ: RENT) is an e-commerce platform that rents designer wear to women through online retail stores as well as its stores.

The firm has its headquarters in Brooklyn, New York and was incorporated in November 2008, by Jennifer Carter Fleiss and Jennifer Y. Hyman. It operates as part of the apparel retail industry, under the consumer cyclical sector. The firm serves consumers in the United States.

The company has developed a 2-sided discovery engine, which connects its differentiated brand partners to customers on a platform built around its technology, logistics, data and brand.

The enterprise provides more than 19,000 styles by over 700 designer brands, helping transform the way women get dressed by letting them wear anything they want, without having to purchase and own it. It affords its customers access to its unlimited closet via its subscription offerings to rent a-la-carte via its reserve offering. The enterprise also gives its customers and subscribers the ability to buy its products via its resale offering. In addition to this, its Closet in the Cloud offering provides an assortment of items for a range of occasions, from ready-to-wear casual, outerwear bottoms and tops, workwear, loungewear, knitwear, kids’ wear and active wear to evening wear.

The company’s recently released financial results show growing revenue, with its CEO noting that they remain focused on making significant progress on their path to profitability. This will positively influence the company’s growth and help create considerable shareholder value.

Rent the Runway Inc. (RENT), closed Thursday's trading session at $3.75, up 6.5341%, on 733,922 volume. The average volume for the last 3 months is 733,922 and the stock's 52-week low/high is $2.99/$24.77.

Warrior Met Coal Inc. (HCC)

MarketBeat, The Online Investor, StreetInsider, Market Report, Zacks, QualityStocks, The Street, Trades Of The Day, Daily Trade Alert, BUYINS.NET, StockMarketWatch, MarketClub Analysis, Schaeffer's, StreetAuthority Daily, AllPennyStocks, Market Intelligence Center Alert, InvestorPlace, Street Insider, CRWEFinance, TopStockAnalysts and SmarTrend Newsletters reported earlier on Warrior Met Coal Inc. (HCC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ideally, we should be moving away from using coal to generate energy in exchange for cleaner, more renewable sources of energy. However, recent events have led to a significant increase in the demand for coal and caused an unprecedented increase in coal prices around the world.

Even though the Russia-Ukraine war has definitely contributed to the increased coal demand, coal prices were on the rise before Russia invaded Ukraine. For example, back in 2020 when the world was right in the thick of the COVID-19 pandemic, Australia called for investigations into the origins of the virus. In retaliation, China banned the import of all Australian goods, including coal, in late 2020 and turned to alternative suppliers to beef up its coal supply.

At that time, coal prices were on the decline, with BMO Capital Markets summarizing that the sector saw a record number of bankruptcies in 2020. As 2021 rolled in and countries started lifting lockdowns, there was a significant increase in power consumption in China and other countries.

However, a relatively tight market for liquified natural gas, coupled with weather conditions unsuitable for renewable energy generation, forced power plants around the world to turn to one of the most abundant and polluting fossil fuels: coal.

Data from the most recent BP Statistical Review of World Energy shows that by the end of 2020, demand for coal had eclipsed 2019 demand by 6%. With more than one-third of the world’s electricity production relying on coal, power plants quickly burned through a significant portion of coal supplies. Global coal supply was also impacted by severe flooding in Indonesia as well as flooding in Australia. All these factors contributed to the increase in coal prices even before the Ukraine-Russia war.

In the wake of Russia’s unprovoked invasion of Ukraine, bans on Russian oil by the European Union, as well as moves by Russia to cut natural gas exports to European nations, have inflated Newcastle coal prices to $400 per ton. Cut off from their usual natural gas supplies, several EU countries said they had no choice but to go back to coal.

This upped demand for a critical energy product that was already wracked with supply issues. The coal industry still hasn’t been able to completely solve the issues that hindered supply last year.

South Africa, the fifth-largest coal supplier in the world, is becoming an alternative to Russian coal. However, an underfunded and poorly performing rail network has capped South Africa’s exporting potential, said Toom Price, an analyst from Liberum.

Natural Coal Association executive director John Ward noted that the U.S. has been facing a crippling shortage of railroad workers, which has impacted the delivery of all products, including coal.

There has also been little investment in new coal mines, said financial services firm Jeffries Group, meaning we can expect supply issues and high prices to continue in the near term, to the benefit of companies such as Warrior Met Coal Inc. (NYSE: HCC).

Warrior Met Coal Inc. (HCC), closed Thursday's trading session at $28.88, up 6.2155%, on 783,870 volume. The average volume for the last 3 months is 783,870 and the stock's 52-week low/high is $15.90/$42.95.

Lucid Motors (LCID)

Green Car Stocks, InvestorPlace, Schaeffer's, MarketClub Analysis, The Street, MarketBeat, QualityStocks, Trades Of The Day, Kiplinger Today, Daily Trade Alert, The Online Investor, StocksEarning, Louis Navellier and Investopedia reported earlier on Lucid Motors (LCID), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The global semiconductor shortage has had a massive impact on the automotive industry, forcing automakers to halt the production of millions of cars. Last May, AlixPartners estimated that automakers could end up losing around $210 billion in revenue in 2021 amid halted production.

And the chip shortage hasn’t just affected traditional cars; the nascent electric vehicle industry, which consumes a lot more semiconductor chips compared to fossil-fuel vehicles, may also see slowed growth in the next few years if the shortage drags on.

According to management consultancy firm P3 Group, electric vehicles require almost twice as many semiconductors as fossil-fuel vehicles, with the average battery electric vehicle (BEV) requiring 1,300 semiconductors compared to 600 for conventional vehicles. A significant portion of these chips is located in the powertrain, the German consultancy agency notes.

The agency’s calculations show that while 2% of total production costs would go to semiconductors in an internal combustion engine (ICE) back in 2017, EV manufacturers will have to dedicate 6% of production costs to semiconductors in 2030. The average electric car requires semiconductor chips in the motor, inverter, charger, DC/AC and central processor.

Don’t forget about the infotainment system and the digital control unit. For electric cars equipped with autonomous driving technology, chips are crucial for the functioning of cameras, ultrasonic sensors, several radars, braking by wire and steering.

P3 Group’s managing director Markus Hackmann says that the consultancy firm realized the significant role semiconductors would play in the EV sector four years ago, stating that these crucial chips would soon be the new battery cells. However, the automotive industry in Germany and the world at large is heavily reliant on semiconductors imported from Asia, a fact the P3 Group refers to as a “repeat mistake.”

Before the coronavirus pandemic hit and caused major supply chain disruptions, Asian countries such as China, Taiwan, South Korea, Malaysia, Singapore, Japan and the Philippines supplied most of the world’s semiconductor chips. Once the pandemic hit and countries issued lockdown orders in 2020, automakers cut their semiconductor orders, fearing a slump in demand. However, demand for chips surpassed the supply even before the pandemic and other electronic segments quickly absorbed this supply.

Furthermore, slowdowns in Asian ports with super-high container throughput such as Shanghai, Shenzhen and Singapore have contributed to the shortage. Rising energy costs have also contributed to increased semiconductor chip costs as the ships that transport them across the seas burn through an incredible amount of expensive oil.

Although automakers such as Tesla and GM have found short-term solutions to the chip shortage, such as foregoing lumbar support from the passenger side and leaving out the start-stop and fuel-management modules, they will require long-term solutions to get around the shortage.

All eyes are now on leading EV makers such as Lucid Motors (NASDAQ: LCID) to see how resilient they can be in the face of such drawn-out challenges at this time when the electric vehicle industry is still in its infancy and poised for takeoff.

Lucid Motors (LCID), closed Thursday's trading session at $19.81, up 8.7267%, on 19,510,416 volume. The average volume for the last 3 months is 19.51M and the stock's 52-week low/high is $13.25/$57.75.

Iconic Brands (ICNB)

Bloomfield Investment Club, QualityStocks, SmallCapVoice, AwesomeStocks, OTCPicks, DSR News, BestDamnPennyStocks, CoolPennyStocks, Global Equity Report, Nebula Stocks, 24-7 Stock Alert, Penny Invest, Penny Stock Hub, TheNextBigTrade, PHUB News, MicroStockProfit, AlphaTrade, Beacon Equity Research, The Observer, StockEgg, Broad Street, Stock Rich, Damn Good Penny Picks, smartOTC, Small Cap Firm, OtcWizard, Light Speed Stocks, Penny Stock Professor, Monster Stock Alerts, Morning Stock Picks, PREPUMP STOCKS, OTCBB Journal, PennyTrader Publisher, TopPennyStockMovers, Penny Picks, Penny Stock Explosion,, Penny Stock Newsletter and HotOTC reported earlier on Iconic Brands (ICNB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Iconic Brands (OTCQB: ICNB), a leader in the development, design and delivery of alcohol and nonalcohol beverages, is changing its name and stock ticker symbol, subject to stockholder and FINRA approval. The company announced that it plans to change its name to TopPop Innovative Brands Inc. and change its existing stock ticker symbol from ICNB to TPOP. In addition, the company named Tom Martin, founder and CEO of TopPop LLC, as interim CEO; Martin has four decades of experience in the packaging industry. Iconic Brands acquired TopPop, now a wholly owned subsidiary, in July 2021. According to the announcement, these key changes reflect the company’s focus on its core growth markets and opportunities, as well as its leadership in sustainable flexible packaging solutions for the food and beverage industry. “I want to express my deep appreciation to the Iconic team members and Iconic investors for making our progress to this point possible,” said Iconic Brands interim CEO Tom Martin in the press release. “I believe TopPop is on a solid growth trajectory. We have built a new 65,000-square-foot facility to expand capacity and to keep up with growing customer demand, and we achieved full-scale production capability at the end of March 2022. In addition, we launched Bellissima Zero, a new line of zero-sugar still wines. I believe it is time to rename the company to align more closely with its core innovative packaging business and prepare the company to list on a national exchange. The sustainable flexible packaging business continues to grow rapidly, as brands and retailers are increasingly looking for U.S. packaging solutions that enhance their products and brand portfolios while also lowering packaging costs and reducing waste. Our capabilities enable our customers to provide a healthier and more environmentally friendly end product to consumers.”

To view the full press release, visit

About Iconic Brands Inc.

Iconic Brands is a leader in the development, design and delivery of alcohol and nonalcohol beverages. TopPop, Iconic’s wholly owned subsidiary, is a leader in the innovation of low-calorie, ready-to-go drinks and ready-to-freeze (“RTF”) and ready-to-drink (“RTD”) products in sustainable, flexible and stand-up pouch packaging, and in the alcohol ice-pop and cocktails-to-go market. Iconic’s brands include Bellissima by Christie Brinkley, a premium better-for-you and better-for-the-planet collection of prosecco, sparkling wines and still wines, all of which are certified vegan and made with organic grapes. Bellissima is strategically positioned with its zero-sugar wines in the zero-sugar beverage category. Iconic operates in multiple states, distributes around the globe and has Fortune 500 customers that include some of the world’s largest alcohol beverage companies and brands. For more information about the company, please visit,, and

Iconic Brands (ICNB), closed Thursday's trading session at $0.3595, up 14.673%, on 577,324 volume. The average volume for the last 3 months is 577,324 and the stock's 52-week low/high is $0.2466/$1.00.

The QualityStocks Company Corner

QSAM Biosciences Inc. (OTCQB: QSAM)

The QualityStocks Daily Newsletter would like to spotlight QSAM Biosciences Inc. (OTCQB: QSAM).

  • QSAM Biosciences Inc. is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients
  • CycloSam(R), QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical being evaluated for multiple indications
  • CycloSam has been shown to cause significantly less buildup of long-lived radionuclidic impurities than prior FDA-approved drugs
  • There is significant precedent that the radioisotope used in CycloSam, Samarium-153, is effective in treating bone cancer, as demonstrated in a published study conducted in over 500 patients using an older formulation of the drug
  • There is also significant preliminary safety precedent for Samarium-153, as shown through the 2020 single patient IND and the super-therapeutic dose administered in that study
  • QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio
  • The company is led be an experienced management team with an extensive record of FDA approvals, big pharma partnerships and M&A transactions

QSAM Biosciences (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted therapeutic radiopharmaceuticals. The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients.

QSAM Biosciences Inc. (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted therapeutic radiopharmaceuticals. The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients.

QSAM Biosciences was founded in 2020 by Executive Chairman Dr. C. Richard Piazza and CEO Douglas Baum. It is headquartered in Austin, Texas.


CycloSam®, QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. By leveraging a patented, low specific activity form of Samarium-153 (resulting in far less undesirable europium impurity) and what management believes to be a superior chelating agent in DOTMP, CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the bone tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters are currently being tested in an FDA-cleared clinical trial.

CycloSam® has been shown in laboratory testing to cause significantly less (30x less) buildup of long-lived radionuclidic impurities than prior FDA-approved drugs, which management believes will enable the ability to safely administer therapeutic doses via higher and multiple-dose regimens and effectively expand its potential clinical utility to therapeutic uses in areas of high unmet medical needs.

The indications for CycloSam® currently being evaluated by QSAM Biosciences include:

  • Metastatic Bone Cancers – On April 28, 2022, QSAM Biosciences announced that the first patient had commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. As noted in the release, the study is a Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam®.
  • Pediatric Osteosarcoma/Ewing’s Sarcoma – On February 2, 2022, the company announced that the U.S. FDA has granted Rare Pediatric Disease Designation to CycloSam for the treatment of osteosarcoma. Combined with a previously granted orphan drug designation for osteosarcoma received in 2021, this milestone “may allow QSAM to potentially bring CycloSam® to market more rapidly through additional incentives and eligibilities,” according to CEO Douglas Baum.
  • Bone Marrow Ablation – In a 2020 single patient Investigational New Drug (IND) study, an investigator concluded that high-dose CycloSam® can be administered safely to ablate bone marrow in advance of a stem cell transplant with no apparent renal toxicity and no unexpected adverse events attributable to the drug.

QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio. The company has secured 14 patents across three distinct patent families spanning the U.S., Japan, Canada and the European Union.

Market Outlook

Through its ongoing development of CycloSam®, QSAM Biosciences is targeting multiple large and underserved market opportunities. According to the American Cancer Society, roughly 400,000 new cases of malignant bone metastasis are diagnosed annually in the U.S. alone. Additionally, QSAM will pursue indications for osteosarcoma and Ewing’s sarcoma that are the most common primary malignancies of bone tissues in children.

Despite this pressing need, the current standard of care for bone cancer is aggressive and suboptimal, leading to marginal success with significant side effects and poor long-term survival prognosis. As a result, QSAM Biosciences estimates a sizable market opportunity for its development pipeline.

  • Bone Metastasis has an estimated total addressable market of $20 billion in the U.S. based on total new cases and comparable drug pricing.
  • Osteosarcoma/Ewing’s Sarcoma have a total addressable market of roughly $125 million in the U.S. based on approximately 1,000 new cases in 2021.
  • The total addressable market for Bone Marrow Ablation is projected at $1 billion, with an estimated 32,000 procedures completed annually.

The company anticipates that the ability to administer CycloSam® for higher and multiple-dose regimens may expand its clinical utility for therapeutic uses in additional areas of high unmet medical needs.

Management Team

QSAM Biosciences is led by an experienced management team and board with an extensive record of FDA approvals, big pharma partnerships and M&A transactions.

Dr. C. Richard Piazza is the Executive Chairman of QSAM Biosciences. Since 2017, he has also served as President and CEO of IGL Pharma Inc., the licensor of CycloSam®, and as a consultant to IsoTherapeutics Group LLC, the inventors of the technology. Dr. Piazza also currently serves on the board of directors of NovaScan LLC, a privately held cancer detection and diagnostics company. He has more than 48 years of health care experience in both medical devices and pharmaceutical/biotech and has led several technology companies to market success, including numerous FDA approvals in both sectors. Dr. Piazza obtained a BS in Economics and a BS in Speech Pathology from the State University of New York and an MA & PhD in Economics from the University of Buffalo and Leeds University.

Douglas R. Baum is the company’s CEO and Director. He brings to QSAM Biosciences over 30 years of experience in the bioscience and biotech industries, including development, FDA/EMA approval and commercialization of multiple drugs and medical devices. Mr. Baum has overseen 15 product approvals through the FDA and EMA and raised over $85 million in capital to fund breakthrough technologies. From 2017 to 2020, he consulted with multiple medical schools and biotech and pharmaceutical companies, and, from 2012 to 2017, he served as President, Chief Executive Officer and Director of Xeris Pharmaceuticals Inc. Mr. Baum holds a Master of Science in Technology Commercialization and a BBA in International Business and Marketing from the University of Texas.

Adam King is the CFO of QSAM Biosciences. He is also the Founder and CEO of King Consulting Group, where he provides a range of financial and reporting services for clients. Before founding King Consulting Group in January 2021, Mr. King was the CFO for Netsertive, a venture-backed digital marketing company. From 2016 to 2018, he was the Office Managing Audit Director for BDO’s Greenville, South Carolina, office, in addition to serving as Audit Director in Raleigh, North Carolina, and Boston, Massachusetts. While at BDO, Mr. King worked with various clients, from tech and life science start-ups to billion-dollar publicly traded companies. He holds a Bachelor of Science in Accounting from Elon University and is a CPA in Raleigh, North Carolina.

QSAM Biosciences Inc. (OTCQB: QSAM), closed Thursday's trading session at $4.44, even for the day, on 100 volume. The average volume for the last 3 months is 100 and the stock's 52-week low/high is $5.00/$26.40.

Recent News

Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

  • The iGaming market is expected to reach $127 billion by 2027
  • Golden Matrix Group provides turnkey gaming platforms giving iGaming operators access to over 10,000 games, state of the art loyalty and customer retention systems
  • GMGI recently acquired and 80% stake in RKings, helping boost revenue 221% in Q1 to $8.48 million as it ventures into the Mexican markets and ESports industry

In 2021, the U.S. commercial gaming industry generated revenue of $53 billion, smashing the previous record set in 2019 at $43.65 billion. With new markets coming online, more records are almost certainly in the cards as evidenced by a Q1 record of $14.1 billion in nationwide revenue to start 2022. Although online gambling, or “iGaming” as it is colloquially called, is still not as popular as its land-based counterpart, the time has come, in the words of, “for online casinos to be in the spotlights.” It’s anticipated that the iGaming market will reach $127 billion by 2027, growth that companies like Golden Matrix Group (NASDAQ: GMGI) intend to capitalize upon.

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.


Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Thursday's trading session at $4.55, up 0.441501%, on 63,721 volume. The average volume for the last 3 months is 63,721 and the stock's 52-week low/high is $3.29/$10.72.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its DehydraTECH licensee Boldt Runners Corporation, owners of the Cannadips brand, has expanded manufacturing agreements to include Europe, Japan and South Africa. “We are delighted with the expansion of the Cannadips brand outside of the USA,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “We continue to work with the Cannadips team on the infusion of exciting new formulations to meet the needs of adult consumers’ changing preferences and will endeavor to always remain one step ahead of the competition.” To view the full press release, visit

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday's trading session at $2.85, up 4.7794%, on 91,807 volume. The average volume for the last 3 months is 91,807 and the stock's 52-week low/high is $1.85/$12.50.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN) is a developer of lidar sensors for advanced driver assistance systems (“ADAS”) and autonomous driving. “The Silicon Valley-based company made D-sample shipments in Q1 in support of GM’s Ultra Cruise program, which is the final stage before scale production, and is on track to potentially be the world’s first lidar company to have its products found in consumer vehicles,” a recent article reads. “High cost has been one major problem with lidar systems for automakers, reserving it to only high-end models. Cepton has helped address this issue with its MMT(R) (micro-motion technology) lidar system, which was developed with mass-market consumer vehicles in mind and has attracted the attention of top automotive OEMs (original equipment manufacturers) and Koito Manufacturing, a leading tier-1 automotive lighting supplier that has invested $100 million in Cepton… GM has agreed to use Cepton lidar products for its first 9 models that will offer Ultra Cruise in 2023 and 2024, and the companies are collaborating on potential additional models that will be introduced in 2025 and beyond. Cepton is currently engaged with all top 10 automotive OEMs worldwide.” To view the full article, visit

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Thursday's trading session at $1.83, up 7.6471%, on 275,732 volume. The average volume for the last 3 months is 275,550 and the stock's 52-week low/high is $1.01/$80.16.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Diagnosing brain tumors in a timely manner can be difficult. Early symptoms of the deadly condition, such as coordination problems and persistent headaches, are common to several other medical conditions. Brain tumor diagnosis usually relies on magnetic resonance imaging (MRI) to spot the tumor and surgery or a biopsy to determine the kind of tumor. But the Brain Tumour Charity estimates that health professionals miss an overwhelming amount of brain cancer cases in their first investigation (99%) and that patients often go years before getting an accurate diagnosis. Researchers from the University of Edinburgh have developed a new verbal fluency test that they say could alleviate the issue of late diagnosis and allow doctors to spot brain cancers early. Dubbed the Noah’s Ark test by the Brain Tumour Society, the verbal fluency test can help healthcare professionals identify common symptoms that may point to an undiagnosed brain tumor. The development of mechanisms through which brain tumors can be detected early is a perfect complement to the search for better treatments by companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) since any treatment administered in the initial stages of a disease stands a higher chance of curing the condition, unlike in situations when a disease has advanced before it is diagnosed.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday's trading session at $0.2823, up 8.4935%, on 593,047 volume. The average volume for the last 3 months is 593,047 and the stock's 52-week low/high is $0.2453/$1.98.

Recent News

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)

The QualityStocks Daily Newsletter would like to spotlight Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF).

  • Daniel Brody, Eat Well’s Co-Founder and Director, has, since June 29, 2022, been buying shares in the company, totaling 8,430,625 as of June 29, 2022
  • His purchases highlight his confidence in the company’s current trajectory and its commitment to creating shareholder value
  • Eat Well maintains that its revenue guidance for its investee companies still stands at $90 million to $110 million for the 2022 fiscal year

The past year was monumental for Eat Well Investment Group (CSE: EWG) (OTC: EWGFF). Most notably, it marked the company’s market expansion following partnerships with vital retail companies in the United States and Canada, with customers in over 35 countries worldwide. In addition, the period saw the company grow its product offering in a move that aimed to grow its market share and create value for its shareholders.

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF), headquartered in Vancouver, British Columbia, is a publicly traded vertically integrated plant-based foods company combining the best of agribusiness, foodtech, and CPG brands to supply the world with innovative, delicious, and better-for-you foods. The company supplies Beyond Meat, Ingredion, Nestle, General Mills and more. It is on track to generate $60 million in revenue for 2021 and is projecting $100 million in revenue for 2022.

Eat Well’s management team has an extensive record of sourcing, financing and building successful companies across a broad range of industries and maintains a current investment mandate on the health and wellness industry. The team has financed and invested in early-stage venture companies for more than 25 years, resulting in the ability to construct a portfolio of opportunistic investments intended to generate superior risk-adjusted returns. Eat Well’s strategic advisory board includes pioneers in the plant-based foods industry, including HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, and Jeff Dunn, CEO of Bolthouse Farms who previously held senior leadership positions at both Campbell Soup Company and The Coca Cola Company.

The company’s plant-based investment thesis is centered on growing its seed-to-market operations, which include raw ingredients, processing, pulse fractionation, unique IP and premium consumer packaged goods (CPG). Eat Well Group is building a unique ecosystem that can supply these essential cornerstone needs for society. The company has plant-based foods and nutrition experts specializing in the latest science and original thinking for what consumers want most – high quality and affordability in healthy, clean and simple products.

Eat Well focuses on intellectual property, product portfolio development and long-term value creation for stakeholders in a rapidly expanding industry. As an emergent sector globally, plant-based foods represent a double-digit annual growth category, with more than 35% of the world’s supply of pulse proteins coming from Canada.


On July 31, 2021, Eat Well Group acquired Belle Pulses Ltd., one of the top pulse processors in Canada. Belle Pulses has been operating for over 40 years and had over $60 million in sales in 2020. The company counts a broad range of customers in over 35 countries, including global strategic food companies and major ingredient distributors. Currently, Belle produces nearly 100,000 tons of fully traceable seed and product, yielding over 26,000 tons of pure plant protein.

Eat Well also owns 100% of Sapientia Technology Inc. Led by Dr. Eugenio Bortone – one of the world’s preeminent food scientists and extrusion processing experts and the inventor of Frito-Lay’s Twisted Cheetos – Sapientia has filed four patents around the “protein curl” and crispy-puff-style snack. By focusing on texture and crunch, Sapientia’s patents solve one of the major problems that large scale snack food companies have struggled with for years – how to offer appealing texture and flavor in a guilt-free, not fried, natural and healthy alternative to the majority of snack food products available today.

Eat Well owns a 51% share of Amara Organic Foods, with an option to acquire additional ownership up to 80 percent. Amara, one of the fastest-growing baby food brands in America, is a food technology company that uses science and proprietary IP that locks in taste and texture to make healthy, organic, non-GMO, plant-based, convenient baby and children’s food possible for modern-day families. From baby food to toddler food and beyond, Amara is driven by the belief that setting kids on the right path from a young age will help them live better, feel better and think better for the rest of their lives. Amara’s revenues have grown by more than 400% since January 2021, and the brand’s success has drawn media coverage from business news outlets including Forbes and TechCrunch.

Market Outlook

According to an August 2021 report from Bloomberg Intelligence, the plant-based foods market is expected to experience explosive growth, comprising up to 7.7% of the global protein market by 2030 at a value of over $162 billion, up from $29.4 billion in 2020. Bloomberg notes that plant-based alternatives are here to stay, and that consumption will grow rapidly. Plant-based food sales in 2020 grew twice as fast as overall food sales, according to Polaris Market Research.

Pulse proteins (fava, yellow pea, etc.) are a foundational ingredient to most plant-based foods due to their high protein content and their readily available, affordable supply.

Many analysts view the food tech market as similar to the early days of the Internet in that plant-based foods represent a worldwide secular trend of steady growth and potential that will revolutionize the way society functions and people experience nutrition.

The sector continues to experience significant M&A transactions. Recently, Sol Cuisine was acquired by PlantPlus Foods LLC, a major South American protein producer, in an all-cash transaction valued at approximately $126 million, or 6x revenue.

Management Team

Marc Aneed is President and Director of Eat Well Group. His 20-year career in CPG started at The Quaker Oats Company/PepsiCo, where he worked on iconic brands like Gatorade. He previously was at Glanbia PLC, a global nutrition company, where he led Amazing Grass, a leading plant nutrition and supplement company with over $100 million in retail sales. He also led Glanbia’s Sports Nutrition brands in North America with over $750 million in retail sales. Mr. Aneed has launched dozens of successful consumer products, driving over $1 billion in collective retail sales.

Mark Coles is the company’s Chief Investment Officer. He is a veteran CPG senior executive specializing in the plant-based foods sector. For the past decade, Mr. Coles has spearheaded global plant-based start-up initiatives, culminating in a 2020 acquisition by an international New York Stock Exchange-listed food ingredient company. He has over 25 years of experience in CPG-focused strategy, mergers and acquisitions and project financing.

Patrick Dunn is Eat Well Group’s Vice President, Finance. He is the founding partner of Dunn, Pariser & Peyrot and has a track record of building highly successful agribusinesses throughout North America and other international markets. As a testimony to his business portfolio work, Mr. Dunn and his firm have won multiple industry awards for accounting, finance and business management.

Barry Didato is the company’s Vice President, Strategy. He is focused on the development of strategic revenue channels, sales partnerships, and international distribution for Eat Well Group. Mr. Didato brings extensive strategic sales capabilities and an extensive network of contacts in the industry to the company. Prior to joining Eat Well Group, he served for over 18 years as a senior advisor for several ultra-high net worth family offices and numerous innovative wellness, nutrition, medical, and food businesses.

Strategic Advisory Board

HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, is a firm supporter of clean energy and the humane treatment of animals. He is also a vocal supporter of the private sector in the Middle East. A member of the Saudi Arabian Royal Family, Prince Khaled was born in Stanford and spent his youth in Riyadh under the mentorship of his father, philanthropist HRH Prince Alwaleed bin Talal Al Saud, Chairman of Kingdom Holding Company. He is also the Founding Chairman of KBW Investments and serves across several boards. He invests in an array of successful but diverse global businesses – from promising technology startups to established companies. Today, with holdings on three continents, Prince Khaled stands at the gateway between the Middle East’s evolving economies and the Western world. Consistently, Prince Khaled’s focus is on ventures and ideas at the intersection of innovation and economic growth.

Jeff Dunn has over 30 years of experience in agriculture and packaged food, including senior leadership positions with Bolthouse Farms, Campbell Soup Company and The Coca Cola Company, among others. He is an Operating Partner at Butterfly and focuses primarily on the agriculture & aquaculture and food & beverage product sectors. Prior to joining Butterfly, Mr. Dunn was the President of the Campbell Fresh division of Campbell Soup Company from 2015 to 2016, where he was in charge of building Campbell’s scale and accelerating its growth in the rapidly expanding packaged fresh segments and categories across the retail perimeter.

Eat Well Investment Group Inc. (OTC: EWGFF), closed Thursday's trading session at $0.16, up 6.8804%, on 19,753 volume. The average volume for the last 3 months is 19,753 and the stock's 52-week low/high is $0.1497/$1.00.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Several psychedelics are outlawed by federal law, with the United States classifying drugs such as psilocybin, LSD, MDMA, mescaline and peyote as Schedule I controlled substances with no accepted medical use. Even though a few states have loosened some of their psychedelic policies, federal law prohibits the production, sale and use of psychedelic drugs. According to two federal health agencies, federal prohibition has forced researchers to jump through numerous regulatory hoops and held back efforts to study the potential benefits and risks of psychedelic drugs. In a four-page letter sent as a response to Sen. Cory Booker’s and Sen. Brian Schatz’s request for an update on psychedelic drug research, the directors of the National Institute of Mental Health (NIMH) and the National Institute on Drug Abuse (NIDA) said that early research showed that psychedelic drugs had medical potential. The federal classification notwithstanding, a number of companies such as Silo Pharma Inc. (OTCQB: SILO) have run the psychedelic research gauntlet and are now focused on developing therapeutic formulations from these substances whose medical value is becoming more apparent with each passing year.

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.


Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Thursday's trading session at $0.1089, up 6.5558%, on 150 volume. The average volume for the last 3 months is 150 and the stock's 52-week low/high is $0.0892/$0.2489.

Recent News

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF).

  • EverGen Infrastructure CEO, Chase Edgelow, was recently featured on IBN’s Bell2Bell podcast
  • Edgelow elucidated on the origins of the company as well as its commercial objectives going forward
  • EverGen recently purchased a 50% stake in an Ontario-based RNG project, with a cumulative production capacity of 1.7 million GJ per year

Chase Edgelow, Co-Founder and CEO of EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF), a British-Columbia based Natural Gas operator, was recently featured on the latest episode of the InvestorBrandNetwork’s Bell2Bell Podcast, with Edgelow seizing on the opportunity to expand on EverGen’s business model and operating markets ( Edgelow separately elaborated on EverGen’s recent announcement of its entry into definitive agreements with Northeast Renewables LP to acquire a 50 percent interest in a portfolio of Ontario-based renewable natural gas (“RNG”) development projects.  

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQB: EVGIF), closed Thursday's trading session at $2.15, even for the day. The average volume for the last 3 months is 100 and the stock's 52-week low/high is $2.12/$4.21.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Advanced Container Technologies (OTC: ACTX) is confident its GrowPods – modular hydroponic greenhouses – could become a valuable tool in efforts to combat food insecurity. With GrowPods, the company notes, cultivation can be moved nearer to the point of consumption, allowing food to be harvested at its peak nutritional value. “Micro-farms, such as ACTX’s Grow Pods, are being evaluated as a potential solution for food insecurity. Last year, Virginia State University (‘VSU’) was given a $500,000 grant to explore micro-farms as a potential solution to what the school called ‘food deserts in urban neighborhoods.’ According to the school, the grant will build VSU’s capacity to provide comprehensive education on micro-farming,” a recent article reads. “Leonard Githinji, project director and sustainable and urban agriculture Cooperative Extension specialist at VSU, reports that more than 11% of the nation’s population and 10% of Virginia’s population are food insecure. ‘Residents in food-insecure areas, commonly known as food deserts, have little or no access to fresh, affordable and nutritious food, and often have higher instances of chronic diseases, such as obesity, due to poor diets,’ Githinji states. ‘Developing sustainable micro-farms in urban areas can have a profound impact on access to healthy food in food deserts.’” To view the full article, visit Last September, California officials announced that the California State Fair would host the country’s first-ever, state-sanctioned marijuana competition. Cannabis vendors from the state would be allowed to compete in the fair in categories such as cheese, beer and wine vendors, a move that pointed to the legitimization of the cannabis industry. The state fair recently unveiled the winners of this historic competition, awarding 60 medals and trophies to companies whose products had been deemed superior by judges via laboratory tests. In a press release, Jess Durfee, the chair of the California Exposition & State Fair Board, said that including marijuana cultivation alongside olive oil, craft beer, wine and cheese was a solid move that perfectly aligned with the state’s rich history of agriculture. With companies such as Advanced Container Technologies Inc. (OTC: ACTX) developing better ways to grow cannabis and other crops, the future competitions may be even closer as companies go all out to take the prized trophies home.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Thursday's trading session at $0.8, off by 5.8824%, on 100 volume. The average volume for the last 3 months is 100 and the stock's 52-week low/high is $0.54/$2.61.

Recent News

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

Odyssey Health (OTC: ODYY) is a Nevada-based medical company developing a variety of drug and technology assets to treat unmet clinical needs. “Odyssey is dedicated to advancing life-saving medical products that offer similar levels of hope to a new generation of people through technological and clinical developments that demonstrate advantages over current standards of care. At the moment, Odyssey’s market profile includes two medical device candidates and two pharmaceutical products in development. The portfolio is responding to varied needs, including patients who may have undiagnosed heart disease, patients choking on some type of obstruction lodged in their throats, patients dealing with a rare neurodegenerative disorder, and patients needing treatment for brain concussion injuries,” a recent article reads. “CEO Michael Redmond spoke with The RedChip Money Report(R) on Bloomberg TV to explain the company’s model… ‘They have strong IP positions – on all three of them,’ Redmond said [of the company’s drug-device combination for treating concussion, a cardiological prototype device, and an anti-choking device]. ‘We believe that we have the management, the board of directors, and the experience level … that will allow us to successfully commercialize all three of these products and create significant value for the company.’” To view the full article, visit

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio


Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
    • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
    • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
    • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
  • Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
    • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Thursday's trading session at $0.2462, off by 8.8148%, on 78,100 volume. The average volume for the last 3 months is 78,100 and the stock's 52-week low/high is $0.11/$0.65.

Recent News


The QualityStocks Daily Newsletter would like to spotlight SPYR Inc. (OTCQB: SPYR).

SPYR (OTCQB: SPYR), dba SPYR Technologies, a diversified technology company developing products and leveraging the Internet of Things (“Iot”) for consumer use and large-scale applications and industries, has announced plans to collaborate with Polte Corporation to use Polte location technologies in two new GeoTraq NB-IoT/LTE-M modules: the Tracker-Module GT-TM100 and Sensor-Module GT-SM100. SPYR recently acquired GeoTraq, a mobile IoT module manufacturer and connectivity provider, and Polte is a leader in advanced Cloud Location over Cellular (“C-LoC”) technology. Using Polte’s proprietary location technology leverages globally available mobile IoT (NB-IoT and LTE-M) networks, thereby eliminating the need for GPS/GNSS radios. Polte’s tech also provides highly accurate tracking indoors, even when objects are inside vehicles or in shipping containers. GeoTraq’s Tracker-Module GT-TM100 is designed specifically for low-cost asset tracking and other location-based intelligent use cases. GeoTraq’s Sensor-Module GT-SM100 offers the fastest, most secure and efficient Mobile IoT connectivity. “We have been working with Polte for over a year, and they have a superior technology for adding location services to our small, low-cost line of Mobile IoT modules,” said GeoTraq chief technology officer Pierre Parent in the press release. “We believe that the business world has not fully grasped the changes that are occurring in the tracking industry and the advancements that positioning on the LTE radio channel will provide. Historical tracking solutions use GPS, which adds $3–$4 in extra component costs and produces a significant drain on the battery life.  If your goal is to build a disposable tracking tag for less than $10 to monitor critical materials and packages while they are in the mail, GPS is a non-starter. It’s too bulky, expensive and probably won’t work indoors. Polte resolves these problems for us, allowing GeoTraq to produce a low-cost module with enhanced location positioning technology.” To view the full press release, visit

SPYR Inc. (OTCQB: SPYR), dba SPYR Technologies, is a technology company which, through its Applied MagiX Inc. subsidiary, develops and resells Apple®-ecosystem-compatible products with an emphasis on the growing, multibillion-dollar Internet of Things (IoT) Smart Home and Connected Car markets.

SPYR continues to identify and target acquisitions with an aim of growing its footprint in the industry and expanding the products it offers consumers, including companies developing artificial intelligence and smart-technology products. In 2020, SPYR acquired Applied MagiX Inc., a registered Apple developer and reseller of Apple ecosystem compatible products with an emphasis on the smart home market, as a wholly owned subsidiary. Applied MagiX operates in the IoT market and, more specifically, the segment of the market related to the development, manufacture and sale of devices and accessories specifically built on Apple’s HomeKit® framework. These products work within the Apple HomeKit ecosystem and are exclusive to the Apple market and its consumers.

Initially, while working to develop, manufacture and sell its own line of branded products, Applied MagiX will be sourcing HomeKit products and accessories from worldwide manufacturers, vetting and selecting best-of-breed products, selling them directly to consumers and supporting them. The company focuses on Apple consumers – a target market with higher disposable income and a demonstrated willingness to pay a premium for quality products. On average, Apple product users spend roughly twice as much on technology as other smartphone users. Those who purchase smart home products spend more than $3,000 on average.

By creating smart hardware and software solutions exclusively for Apple consumers, SPYR addresses a problem faced by that market – having few “smart” devices that integrate with Apple’s HomeKit, despite being the most affluent and loyal consumers of tech products.


The company’s Applied MagiX subsidiary offers multiple product lines to its target markets. First, the subsidiary is a reseller of third-party manufactured Apple HomeKit and Apple CarPlay compatible products. HomeKit comes pre-installed on every new iPhone, while the CarPlay platform is licensed by all major auto manufacturers. Applied MagiX identifies white label products, applies the company’s branding, improves the software and sells these improved products to consumers. Finally, Applied MagiX is developing its own proprietary line of smart home and connected car products, including Apple-compatible home cameras, sensors and alarms, as well as additional Apple-compatible smart car products in the iOS ecosystem.

Among the subsidiary’s products sold to consumers are:

  • The MagixDrive Wireless CarPlay adapter, which allows users to access CarPlay wirelessly using their iPhones
  • The HomeKit Secure Video Camera with iCloud Storage
  • The Multipurpose Sensor with Alarm
  • The Environment and Motion Sensor
  • The Window and Door Contact Sensor

Market Outlook

According to Statista, the global smart home market is expected to generate revenue of more than $104 billion in 2021. The market is forecast to hit more than $187 billion in revenue by 2025, recording a CAGR of 15.75 percent.

The number of active households in the worldwide smart home market is expected to reach nearly 500 million by 2025. Household penetration is just over 12 percent in 2021 and is projected to nearly double by 2025 to more than 22 percent.

Allied Market Research valued the global connected car market at more than $63 billion in 2019 and projected a CAGR of 17.1 percent, which would push revenue to more than $225 billion by 2027. Allied identified rising consumer demand for connectivity solutions, surging need for constant connectivity, increasing dependency on technology and an upsurge in tech-savvy population as key factors driving the projected growth of the connected car market.

Management Team

James R. Thompson is the CEO, President and General Counsel of SPYR. Over the past 28 years, Mr. Thompson has deftly managed a colorful spectrum of legal clients and situations. In the process, he has helped many companies – both large and small – thrive. Now he welcomes the challenge to take the company and his career in an entirely new direction. A native of Philadelphia, he holds a J.D. from Rutgers University and a Bachelor of Science from the University of Denver.

Jennifer Duettra is the Executive Vice President of SPYR. She brings a great deal of knowledge in mobile gaming and pop culture to the company. She is an attorney and was thrilled by the prospect to combine her law experience with a chance to be creative. She is a native of Colorado and received her Bachelor of Arts in Political Science and Speech Communication from Colorado State University. She holds a J.D. from Harvard University.

Trang Nguyen is the CFO of SPYR. From 2019 to 2020, she served as the Financial Reporting Manager for Del Taco, where she was responsible for the preparation and filing of periodic financial reports with the U.S. Securities and Exchange Commission. From 2016 through 2019, Ms. Nguyen was Accounting Manager for Pinnacle Tax Accounting in Los Angeles, California. She was a part of Ernst & Young’s audit team in Los Angeles from 2006 to 2008, leading engagements on interim and year-end ad SOX 404 auditing procedures for major enterprise accounts. Ms. Nguyen holds a Bachelor of Art, Business Economics (Minor in Accounting) from the University of California, Los Angeles. She is a certified public accountant with an inactive license.

Dr. Harald Zink is the CEO, Founder and Chief Product Architect of SPYR subsidiary Applied MagiX. Prior to founding Applied MagiX, he was Director of Technologies and later Vice President of Technologies at Sarkissian Productions in Los Angeles. He also served as Director of Technologies at SMZ Technologies and, for more than 17 years, as Macintosh Technology Consultant to The Walt Disney Studios in Burbank, California. He speaks five languages and holds degrees from the University of California, Riverside.

Kelly Clark is the COO of Applied MagiX. Before joining the subsidiary, he worked as Vice President of Sales Operations at TruClear Global. Prior to that, Mr. Clark was Senior Director of Program Management at Pacific Group Ventures and Operations Manager at Barco. He has also held operations management positions at Deluxe Digital Studios and Sony Pictures Entertainment. Mr. Clark holds a bachelor’s degree in international business from the University of Southern California.

SPYR Inc. (OTCQB: SPYR), closed Thursday's trading session at $0.022, off by 5.6806%, on 2,018,568 volume. The average volume for the last 3 months is 1.919M and the stock's 52-week low/high is $0.018/$0.09935.

Recent News

Cannabis Strategic Ventures Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures Inc. (NUGS).

America’s cannabis industry is projected to grow from $28 billion in 2021 to $197 billion in 2028 at a compound annual growth rate (CAGR) of 32.04%. Given the increased evidence of its medical potential coupled with how well the cannabis industry weathered the coronavirus pandemic and industry projections, plenty of investors have had their eyes on cannabis. But despite marijuana’s awesome growth potential, it is still susceptible to market factors with the ability to limit or enhance its growth. Public sentiment is one such factor. Cannabis has been criminalized for decades in the United States, with millions of Americans being led to believe that it is just as dangerous as deadly drugs such as cocaine and heroin. Surveys now show that the majority of Americans support cannabis reform, and these attitudes have spread to other countries. Several territories have now legalized the drug, while many more are bound to as public sentiment about cannabis changes. Marijuana companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS) have to find a way to balance the impact of all those factors as they plan their operations and future offerings.

Cannabis Strategic Ventures Inc. (OTC: NUGS) is an emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator. The company is based in Los Angeles, with a 6-acre cannabis farm in Northern California called NUGS Farm North. The company’s vision is to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration.

Cannabis Strategic Ventures recently expanded its portfolio by completing the transfer process for cultivation, retail, distribution and manufacturing licenses issued by the City of Los Angeles and the State of California, and it is now working toward taking operational control of each license. The company also recently announced the upcoming grand opening of its cannabis dispensary, MDRN Tree. Following that launch, Cannabis Strategic Ventures intends to deploy another of its new licenses to establish an indoor cultivation facility with capacity to produce two to three pounds of premium exotic cannabis flower per light per harvest. The facility will have up to 1,200 grow lights and is anticipated to yield 5.75 harvests per year, bringing it to a total production capacity of over 15,000 pounds of cannabis flower annually.

Brand Portfolio

The company owns multiple brands under the Cannabis Strategic Ventures umbrella. The firm’s NUGS brand provides operational and financial strategic partnerships and a range of essential services to emerging and existing cannabis consumer brands.

The NUGS Farm North brand operates as a six-and-a-half-acre cannabis cultivation property located in northern California. The company believes that the key to success in its business is consistent quality and reliable supply to fit growing consumer demand. Cannabis Strategic Ventures addressed these consumer needs by building NUGS Farm North. At NUGS Farm North, the company’s process is customized, and its product is consistent. Located in the heart of an agricultural mecca for globally distributed produce, NUGS Farm North finds power in its product, not in its size. Decades of agricultural experience and a dedication to consistency ensure quality cannabis.

MDRN Tree is Cannabis Strategic Ventures’ customer-facing dispensary brand. MDRN Tree will open its first Los Angeles location sometime in the fall of 2021. MDRN Tree will be the company’s factory retail store – a direct interface with the end-market community – where Cannabis Strategic Ventures plans on showcasing the cannabis flower produced at its NUGS Farm North cultivation site. This farm-to-sale model offers the potential to drive simultaneous gains in quality control and profitability.

Market Outlook

The demand for legal marijuana is expected to surge due to ongoing changes in U.S. state government policies toward cannabis. In addition, the number of indications for which medical marijuana is prescribed continues to increase steadily. These factors are expected to rapidly boost legal sales of cannabis products, opening new revenue channels for producers and retailers. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will only present more high growth opportunities for this market.

According to a report from Grand View Research, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a compound annual growth rate of 26.7 percent from 2021 to 2028. That CAGR would put the market value at roughly $30 billion as soon as 2025.

According to the report, “One of the major factors fueling market growth is the expanding demand for legal marijuana owing to the growing number of legal cannabis countries. (Due) to recent legalizations in different countries, the use of medical marijuana for various ailments is gaining momentum worldwide. Patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s, and many neurological disorders are administered medical marijuana. The demand for cannabis oil is increasing rapidly, especially among countries with legalized medical marijuana.”

Management Team

Simon Yu is CEO, President, CFO and Secretary of Cannabis Strategic Ventures. He is also a co-founder, former COO and board member of Clubhouse Media Group Inc., a publicly traded social media company. Mr. Yu holds an MBA from the University of Southern California.

Cannabis Strategic Ventures Inc. (NUGS), closed Thursday's trading session at $0.014, off by 1.4085%, on 210,100 volume. The average volume for the last 3 months is 210,100 and the stock's 52-week low/high is $0.0103/$0.073.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.